{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001305","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.014144+00:00","generated_at":"2026-06-11T22:45:06.667330+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Scholar Rock Q2 net loss $37.9M; cash $249M; SAPPHIRE enrollment on track for Q3 2023","bullets":["Net loss $37.9M in Q2 2023 vs $44.0M in Q2 2022; no revenue for either period.","Cash, equivalents & marketable securities $249M as of Jun 30, 2023; expected to fund into 2025.","Phase 3 SAPPHIRE trial enrollment completion expected Q3 2023; top-line data in 2H 2024.","36-month extension data from Phase 2 TOPAZ showed substantial sustained motor function improvement.","Clinical & biomarker update from DRAGON Part B (SRK-181) anticipated in 2H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001305","json":"https://secwatch.observer/filing/0001157523-23-001305.json","markdown":"https://secwatch.observer/filing/0001157523-23-001305.md","text":"https://secwatch.observer/filing/0001157523-23-001305.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000115752323001305/0001157523-23-001305-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000115752323001305/a53519737.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T22:45:06.667330+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"693906404cb88378a49d9804459b61c2c868fd89","claim":"Scholar Rock Holding Corp reported the quarter ended June 30, 2023 results: net income $37.9 million.","evidence_excerpt":"For the quarter ended June 30, 2023, net loss was $37.9 million compared to a net loss of $44.0 million for the quarter ended June 30, 2022. The Company did not record any revenue for either the quarter ended June 30, 2023 or June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1727196/000115752323001305/0001157523-23-001305-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"$37.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}